Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Liabilities (2016 - 2025)

United Therapeutics (UTHR) has disclosed Total Liabilities for 17 consecutive years, with $783.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 14.8% to $783.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $783.8 million through Dec 2025, down 14.8% year-over-year, with the annual reading at $783.8 million for FY2025, 14.8% down from the prior year.
  • Total Liabilities hit $783.8 million in Q4 2025 for United Therapeutics, up from $760.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.3 billion in Q3 2023 to a low of $734.4 million in Q2 2025.
  • Historically, Total Liabilities has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2021.
  • Biggest five-year swings in Total Liabilities: increased 10.97% in 2021 and later decreased 28.42% in 2025.
  • Year by year, Total Liabilities stood at $1.2 billion in 2021, then grew by 3.11% to $1.2 billion in 2022, then fell by 5.26% to $1.2 billion in 2023, then dropped by 22.18% to $920.0 million in 2024, then fell by 14.8% to $783.8 million in 2025.
  • Business Quant data shows Total Liabilities for UTHR at $783.8 million in Q4 2025, $760.9 million in Q3 2025, and $734.4 million in Q2 2025.